CEA, CA 242, CA 19-9, CA 72-4 and hCGβ in the diagnosis of recurrent colorectal cancer

Tumor Biology

Volumn 25, Issue 5-6, 2004, Pages 228-234

  Carpelan Holmström, Monika ^a   Louhimo, Johanna ^a   Stenman, Ulf Håkan ^a   Alfthan, Henrik ^a   Järvinen, Heikki ^a   Haglund, Caj ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

CA 19 9; CA 242; CA 72 4; CEA; Colorectal cancer; Follow up; Human chorionic gonadotropin ; Logistic regression; Neoplasm; Tumour marker

Indexed keywords

CA 19-9 ANTIGEN; CA 242 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; INFORMATION PROCESSING; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PATIENT SELECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TECHNIQUE; TUMOR LOCALIZATION;

EID: 11444255020     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081385     Document Type: Article

References (24)

1. Cromheecke M, de Jong KP, Hoekstra HJ: Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol 1999;25:451-463.
2. Wagner JS, et al: The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984;199:502-508.
3. Brister SJ, et al: Contemporary operative management of pulmonary metastases of colorectal origin. Dis Colon Rectum 1988;31:786-792.
4. Duffy MJ: Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin Chem 2001;47:624-630.
5. Duffy MJ, et al: Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718-727.
6. Lucha PA Jr, et al: Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma. Dis Colon Rectum 1997;40:145-149.
7. Kuusela P, Haglund C, Roberts PJ: Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer 1991;63:636-640.
8. Filella X, et al: Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg 1992;216:55-59.
9. Nilsson O, et al: Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br J Cancer 1992;65:215-221.
10. Carpelan-Holmström M, et al: Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Br J Cancer 1996;74:925-929.
11. Hall NR, et al: The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer. Br J Cancer 1994;70:549-553.
12. Carpelan-Holmström MA, et al: Serum CA 242 and CEA detect different patients with recurrent colorectal cancer. Anticancer Res 1996;16:981-986.
13. Louhimo J, et al: Combination of HCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies. Anticancer Res 2002;22:1759-1764.
14. Fernandez-Fernandez L, Tejero E, Tieso A: Significance of CA 72-4 in colorectal carcinoma. Comparison with CEA and CA 19-9. Eur J Surg Oncol 1995;21:388-390.
15. Guadagni F, et al: TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. Cancer 1993;72:2098-2106.
16. Carpelan-Holmström M, et al: Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 2004;66:296-302.
17. Alfthan H, et al: Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res 1992;52:4628-4633.
18. Marcillac I, et al: Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res 1992;52:3901-3907.
19. Hosmer D: Applied Logistic Regression, ed 2. New York, John Wiley & Sons, 2000, p 373.
20. Davis NC, et al: Staging of colorectal cancer. The Australian clinico-pathological staging (ACPS) system compared with Dukes' system. Dis Colon Rectum 1984;27:707-713.
21. Alfthan H, et al: Choriogonadotropin and its beta subunit separated by hydrophobic-interaction chromatography and quantified in serum during pregnancy by time-resolved immunofluorometric assays. Clin Chem 1988;34:1758-1762.
22. Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.
23. Carpelan-Holmström M, et al: CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002;22:2311-2316.
24. Louhimo J, et al: Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002;101:545-548.